UA105181C2 - Похідні піридазину як інгібітори smo - Google Patents
Похідні піридазину як інгібітори smoInfo
- Publication number
- UA105181C2 UA105181C2 UAA201100571A UAA201100571A UA105181C2 UA 105181 C2 UA105181 C2 UA 105181C2 UA A201100571 A UAA201100571 A UA A201100571A UA A201100571 A UAA201100571 A UA A201100571A UA 105181 C2 UA105181 C2 UA 105181C2
- Authority
- UA
- Ukraine
- Prior art keywords
- methods
- agents
- tumor
- hedgehog
- present
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/20—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
В заявці описані нові сполуки, що застосовуються при діагностиці та лікуванні патологій, пов'язаних із шляхом Hedgehog, включаючи, але не обмежуючись тільки ними, утворення пухлини, рак, неоплазію та незлоякісні гіперпроліферативні порушення. В заявці описані нові сполуки, нові композиції, способи їх застосування та способи їх одержання. Tакі сполуки зазвичай є фармакологічно корисними як засоби для лікування, механізм дії яких включає пригнічення онкогенезу, росту пухлини та життєдіяльності пухлини за допомогою засобів, які інгібують шлях передачі сигналу Hedgehog та Smo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8190008P | 2008-07-18 | 2008-07-18 | |
PCT/EP2009/059138 WO2010007120A1 (en) | 2008-07-18 | 2009-07-16 | Pyridazine derivatives as smo inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
UA105181C2 true UA105181C2 (uk) | 2014-04-25 |
Family
ID=41130287
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UAA201100571A UA105181C2 (uk) | 2008-07-18 | 2009-07-16 | Похідні піридазину як інгібітори smo |
Country Status (44)
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20220154322A1 (en) * | 2019-03-07 | 2022-05-19 | Suzhou Microport Orthorecon Co., Ltd. | Preparation method and application of oxidized ceramic layer on surface of zirconium and zirconium alloy |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI433674B (zh) | 2006-12-28 | 2014-04-11 | Infinity Discovery Inc | 環杷明(cyclopamine)類似物類 |
NZ588001A (en) | 2008-04-29 | 2012-06-29 | Lilly Co Eli | Disubstituted phthalazine hedgehog pathway antagonists |
US20100041663A1 (en) * | 2008-07-18 | 2010-02-18 | Novartis Ag | Organic Compounds as Smo Inhibitors |
US8536176B2 (en) * | 2008-08-01 | 2013-09-17 | Nippon Chemiphar Co., Ltd. | GPR119 agonist |
EP2346499A1 (en) * | 2008-10-01 | 2011-07-27 | Novartis AG | Smoothened antagonism for the treatment of hedgehog pathway-related disorders |
PT2364185E (pt) | 2008-11-03 | 2013-07-24 | Lilly Co Eli | Ftalazina dissubstituída antagonista da via hedgehog |
EP2358698B1 (en) | 2008-11-17 | 2012-09-05 | Eli Lilly and Company | Tetrasubstituted pyridazine as hedgehog pathway antagonists |
WO2010056620A1 (en) | 2008-11-17 | 2010-05-20 | Eli Lilly And Company | Tetrasubstituted pyridazines hedgehog pathway antagonists |
AR077014A1 (es) | 2009-06-19 | 2011-07-27 | Lilly Co Eli | Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer |
KR20120107962A (ko) * | 2009-11-18 | 2012-10-04 | 노파르티스 아게 | 고형 종양 및 다른 악성종양의 치료를 위한 방법 및 조성물 |
CA2784710A1 (en) * | 2009-12-15 | 2011-06-23 | Shionogi & Co., Ltd. | Oxadiazole derivative having endothelial lipase inhibitory activity |
AR080908A1 (es) | 2010-04-16 | 2012-05-16 | Novartis Ag | Formulaciones de un piridazin -bipirazinilo |
EA201291236A1 (ru) | 2010-05-13 | 2013-11-29 | Эмджен Инк. | Азотные гетероциклические соединения, применимые в качестве ингибиторов pde10 |
EP2511273B8 (en) * | 2011-04-15 | 2019-06-26 | Hivih | Inhibitors of viral replication, their process of preparation and their therapeutical uses |
KR20140026537A (ko) | 2011-06-02 | 2014-03-05 | 노파르티스 아게 | 헤지호그 억제제 요법을 위한 바이오마커 |
SG11201502137YA (en) * | 2012-09-21 | 2015-04-29 | Agency Science Tech & Res | A method for treating a disease or disorder of the lung by inhibition of the hedgehog pathway |
GB201309508D0 (en) * | 2013-05-28 | 2013-07-10 | Redx Pharma Ltd | Compounds |
EP2821104A1 (en) | 2013-07-05 | 2015-01-07 | Laboratoire Biodim | Inhibitors of viral replication, their process of preparation and their therapeutical uses |
WO2015101957A2 (en) | 2014-01-06 | 2015-07-09 | Rhizen Pharmaceuticals Sa | Novel glutaminase inhibitors |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
AU2015229103C9 (en) | 2014-03-14 | 2020-11-26 | Immutep S.A.S | Antibody molecules to LAG-3 and uses thereof |
MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
TWI716362B (zh) | 2014-10-14 | 2021-01-21 | 瑞士商諾華公司 | 針對pd-l1之抗體分子及其用途 |
US20170340733A1 (en) | 2014-12-19 | 2017-11-30 | Novartis Ag | Combination therapies |
JP6692826B2 (ja) | 2015-03-10 | 2020-05-13 | アドゥロ バイオテック,インク. | 「インターフェロン遺伝子刺激因子」依存性シグナル伝達の活性化のための組成物及び方法 |
EP3302428A1 (en) | 2015-06-04 | 2018-04-11 | Pellepharm Inc. | Topical formulations for delivery of hedgehog inhibitor compounds and use thereof |
LT3317301T (lt) | 2015-07-29 | 2021-07-26 | Novartis Ag | Kombinuotos terapijos, apimančios antikūno molekules prieš lag-3 |
US20180222982A1 (en) | 2015-07-29 | 2018-08-09 | Novartis Ag | Combination therapies comprising antibody molecules to pd-1 |
EP3316902A1 (en) | 2015-07-29 | 2018-05-09 | Novartis AG | Combination therapies comprising antibody molecules to tim-3 |
JP2019500893A (ja) | 2015-11-03 | 2019-01-17 | ヤンセン バイオテツク,インコーポレーテツド | Pd−1及びtim−3に特異的に結合する抗体及びそれらの使用 |
US20180371093A1 (en) | 2015-12-17 | 2018-12-27 | Novartis Ag | Antibody molecules to pd-1 and uses thereof |
AU2017281907B2 (en) * | 2016-06-23 | 2021-10-21 | St. Jude Children's Research Hospital, Inc. | Small molecule modulators of pantothenate kinases |
US11098077B2 (en) | 2016-07-05 | 2021-08-24 | Chinook Therapeutics, Inc. | Locked nucleic acid cyclic dinucleotide compounds and uses thereof |
US10548908B2 (en) | 2016-09-15 | 2020-02-04 | Nostopharma, LLC | Compositions and methods for preventing and treating heterotopic ossification and pathologic calcification |
CN106831718B (zh) * | 2016-12-30 | 2019-05-07 | 上海科技大学 | 平滑受体配体及其应用 |
EP3606915A1 (de) * | 2017-04-05 | 2020-02-12 | Bayer CropScience Aktiengesellschaft | 2-amino-5-oxyalkyl-pyrimidinderivate und deren verwendung zur bekämpfung unerwünschten pflanzenwachstums |
UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
EP3642240A1 (en) | 2017-06-22 | 2020-04-29 | Novartis AG | Antibody molecules to cd73 and uses thereof |
WO2019133632A1 (en) | 2017-12-27 | 2019-07-04 | St. Jude Children's Research Hospital | Methods of treating disorders associated with castor |
WO2019133635A1 (en) | 2017-12-27 | 2019-07-04 | St. Jude Children's Research Hospital | Small molecule modulators of pantothenate kinases |
TW202015726A (zh) | 2018-05-30 | 2020-05-01 | 瑞士商諾華公司 | Entpd2抗體、組合療法、及使用該等抗體和組合療法之方法 |
JP2022548881A (ja) | 2019-09-18 | 2022-11-22 | ノバルティス アーゲー | Entpd2抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法 |
CN114042069B (zh) * | 2021-10-22 | 2024-07-19 | 陕西国际商贸学院 | 一种5-取代哒嗪-4-胺衍生物、制备方法和用途 |
WO2023101438A1 (ko) * | 2021-11-30 | 2023-06-08 | 주식회사 헤지호그 | Smo 인간 항체 |
Family Cites Families (86)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1293565A (en) | 1969-05-03 | 1972-10-18 | Aspro Nicholas Ltd | Aminophthalazines and pharmaceutical compositions thereof |
US3668207A (en) * | 1970-01-22 | 1972-06-06 | Ciba Geigy Corp | 2-amino-4-aryl-quinolines |
DE2643753A1 (de) | 1976-09-29 | 1978-04-06 | Thomae Gmbh Dr K | Neue 1h-pyrazolo eckige klammer auf 3,4-b eckige klammer zu pyridine |
FR2421900A1 (fr) | 1977-03-17 | 1979-11-02 | Sauba Lab | Piperazino-3-indoles, leur procede de preparation et leurs applications therapeutiques |
FI70411C (fi) * | 1980-12-29 | 1986-09-19 | Pfizer | Foerfarande foer framstaellning av nya antihypertensiva 4-amino-6,7-dimetoxi-2-piperazinokinazolin derivat |
US5001125A (en) | 1984-03-26 | 1991-03-19 | Janssen Pharmaceutica N.V. | Anti-virally active pyridazinamines |
US4569934A (en) * | 1984-10-09 | 1986-02-11 | American Cyanamid Company | Imidazo[1,2-b]pyridazines |
US4734418A (en) * | 1984-12-14 | 1988-03-29 | Mitsui Petrochemical Industries, Ltd. | Quinazoline compounds and antihypertensives |
US4760064A (en) * | 1984-12-18 | 1988-07-26 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril compounds, compositions containing same and processes for preparing same |
JP2544939B2 (ja) | 1987-09-01 | 1996-10-16 | 大塚製薬株式会社 | ベンゾヘテロ環誘導体 |
JPH0531271Y2 (uk) | 1987-10-14 | 1993-08-11 | ||
JPH02193992A (ja) | 1989-01-23 | 1990-07-31 | Kyowa Hakko Kogyo Co Ltd | キナゾリン誘導体 |
JPH03106875A (ja) | 1989-09-20 | 1991-05-07 | Morishita Pharmaceut Co Ltd | 1―(3―ピリジルメチル)フタラジン誘導体 |
NZ290952A (en) | 1994-08-09 | 1998-05-27 | Eisai Co Ltd | Phthalazine derivatives optionally substituted in position-1 by (generally benzyl) amino groups |
US5889006A (en) | 1995-02-23 | 1999-03-30 | Schering Corporation | Muscarinic antagonists |
US5859012A (en) | 1996-04-03 | 1999-01-12 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5935958A (en) * | 1996-07-01 | 1999-08-10 | Schering Corporation | Muscarinic antagonists |
EP1082308B1 (de) | 1998-04-20 | 2009-04-01 | Abbott GmbH & Co. KG | Heterocyclisch substituierte amide als calpainhemmer |
CA2336000C (en) | 1998-06-30 | 2006-10-10 | Schering Corporation | N-substituted piperazines and 1,4-disubstituted piperidines |
US6066636A (en) * | 1998-06-30 | 2000-05-23 | Schering Corporation | Muscarinic antagonists |
BR9916618A (pt) | 1999-01-28 | 2001-10-23 | Bristol Myers Squibb Co | Compostos heterocìclicos antidepressivos |
JP2000281660A (ja) | 1999-03-29 | 2000-10-10 | Sumitomo Pharmaceut Co Ltd | キナゾリン誘導体 |
ES2265929T3 (es) | 1999-03-30 | 2007-03-01 | Novartis Ag | Derivados de ftalazina para el tratamiento de enfermedades inflamatorias. |
ATE299865T1 (de) | 1999-05-04 | 2005-08-15 | Schering Corp | Piperazinderivate verwendbar als ccr5 antagonisten |
ES2165274B1 (es) | 1999-06-04 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de indolilpiperidina como agentes antihistaminicos y antialergicos. |
ES2233383T3 (es) | 1999-06-08 | 2005-06-16 | Lorantis Limited | Utilizacion terapeutica de un ihibidor de la via de señalizacion hedgehog. |
FR2803593B1 (fr) * | 2000-01-06 | 2002-02-15 | Sanofi Synthelabo | Nouvelles tetrahydropyridines, procede pour leur preparation et compositions pharmaceutiques les contenant |
DK1277754T3 (da) | 2000-04-27 | 2005-11-14 | Astellas Pharma Inc | Imidazopyridinderivater |
DE10043659A1 (de) | 2000-09-05 | 2002-03-14 | Merck Patent Gmbh | Arylpiperazinderivate |
ES2172436B1 (es) | 2000-10-31 | 2004-01-16 | Almirall Prodesfarma Sa | Derivados de indolilpiperidina como agentes antihistaminicos y antialergicos. |
EP1353674A1 (en) | 2000-12-29 | 2003-10-22 | Alteon, Inc. | Method for treating glaucoma ivb |
SE0103754L (sv) | 2001-04-05 | 2002-10-06 | Forskarpatent I Syd Ab | Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid |
EP1401469A2 (en) | 2001-04-09 | 2004-03-31 | Lorantis Limited | Therapeutic use and identification of modulators of a hedgehog signalling pathway or one of its target pathways |
JP4929547B2 (ja) | 2001-09-03 | 2012-05-09 | コニカミノルタホールディングス株式会社 | アゾメチン化合物、アゾメチン化合物と金属イオン含有化合物との混合物、感熱転写記録材料、カラートナー |
JP4637481B2 (ja) | 2001-10-19 | 2011-02-23 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | Cds1/chk2阻害剤および癌治療における化学療法または放射線療法の補助剤としての2−フェニルベンズイミダゾールおよびイミダゾ−[4,5]−ピリジン |
JP4455064B2 (ja) * | 2002-03-27 | 2010-04-21 | グラクソ グループ リミテッド | キノリン誘導体および5−ht6リガンドとしてのその使用 |
DE60322869D1 (de) | 2002-04-22 | 2008-09-25 | Univ Johns Hopkins | Modulatoren von hedgehog signalpfaden, zusammensetzungen und verwandte verwendungen |
EP1606282B1 (en) | 2003-02-24 | 2008-11-12 | Arena Pharmaceuticals, Inc. | Phenyl- and pyridylpipereidinye-derivatives as modulators of glucose metabolism |
AU2004261249B2 (en) * | 2003-07-30 | 2008-09-04 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives and their use as therapeutic agents |
DE10337184A1 (de) | 2003-08-13 | 2005-03-10 | Gruenenthal Gmbh | Substituierte 3-Pyrrolidin-Indol-Derivate |
EP1663962A4 (en) | 2003-08-22 | 2007-08-22 | Dendreon Corp | COMPOSITIONS AND METHODS FOR TREATING A DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION |
WO2005033288A2 (en) | 2003-09-29 | 2005-04-14 | The Johns Hopkins University | Hedgehog pathway antagonists |
AU2005249380C1 (en) | 2004-04-23 | 2012-09-20 | Exelixis, Inc. | Kinase modulators and methods of use |
CN102964294A (zh) | 2004-09-02 | 2013-03-13 | 遗传技术研究公司 | Hedgehog信号转导的吡啶基抑制剂 |
GB0422263D0 (en) * | 2004-10-07 | 2004-11-10 | Glaxo Group Ltd | Novel compounds |
US7759337B2 (en) | 2005-03-03 | 2010-07-20 | Amgen Inc. | Phthalazine compounds and methods of use |
DE102005023943A1 (de) | 2005-05-20 | 2006-11-23 | Grünenthal GmbH | Pentafluorsulfanyl-substituierte Verbindung und deren Verwendung zur Herstellung von Arzneimitteln |
JP5118029B2 (ja) * | 2005-06-14 | 2013-01-16 | タイゲン バイオテクノロジー カンパニー,リミテッド | ピリミジン化合物 |
US8364148B2 (en) * | 2005-07-07 | 2013-01-29 | Qualcomm Incorporated | Methods and devices for interworking of wireless wide area networks and wireless local area networks or wireless personal area networks |
JO2769B1 (en) | 2005-10-26 | 2014-03-15 | جانسين فارماسوتيكا ان. في | Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor |
DK1957461T3 (en) * | 2005-11-14 | 2016-12-19 | Genentech Inc | Bisamidhæmmere the hedgehog-signalling |
CA2630884A1 (en) | 2005-11-30 | 2007-06-07 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-met and uses thereof |
US8541406B2 (en) * | 2006-02-07 | 2013-09-24 | Nv Remynd | Thiadiazole derivatives for the treatment of neurodegenerative diseases |
TWI417095B (zh) * | 2006-03-15 | 2013-12-01 | Janssen Pharmaceuticals Inc | 1,4-二取代之3-氰基-吡啶酮衍生物及其作為mGluR2-受體之正向異位性調節劑之用途 |
BRPI0709035A2 (pt) | 2006-03-21 | 2011-06-21 | Schering Corp | compostos de piridina substituìda heterocìclica com atividade antagonista de cxcr3 |
BRPI0710938A2 (pt) | 2006-04-28 | 2012-06-26 | Univ Northwestern | formulações contendo compostos de piridazina para o tratamento de doenças neuroinflamatórias |
CA2650704A1 (en) * | 2006-04-28 | 2007-11-08 | Northwestern University | Salts of pyridazine compounds |
WO2007127475A2 (en) * | 2006-04-28 | 2007-11-08 | Northwestern University | Pyridazines for demyelinating diseases and neuropathic pain |
EP1849781A1 (en) * | 2006-04-28 | 2007-10-31 | Laboratorios del Dr. Esteve S.A. | Substituted 3-Amino-4-hydroxy pyrrolidines compounds, their preparation and use as medicaments |
CA2658417A1 (en) | 2006-07-14 | 2008-01-17 | Schering Corporation | Heterocyclic substituted piperazine compounds with cxcr3 antagonist activity |
GB0623258D0 (en) * | 2006-11-22 | 2007-01-03 | Remynd Nv | Thiadiazole derivatives for the treatment of neuro-degenerative diseases |
US8680012B2 (en) | 2006-12-14 | 2014-03-25 | Syngenta Crop Protection Llc | 4-phenyl-pyrane-3,5-diones,4-phenyl-thiopyrane-3,6-diones and cyclohexanetriones as novel herbicides |
JP2010513520A (ja) * | 2006-12-22 | 2010-04-30 | シェーリング コーポレイション | Cxcr3アンタゴニスト活性を有する複素環式化合物 |
JO2849B1 (en) | 2007-02-13 | 2015-03-15 | جانسين فارماسوتيكا ان. في | Dopamine 2 receptor antagonists are rapidly hydrolyzed |
TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
TW200900391A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-phenyl-piperidin-1-yl)-pyridin-2-one derivatives |
EP2121579B1 (en) | 2007-03-15 | 2011-04-20 | F. Hoffmann-La Roche AG | Malonamides as orexin antagonists |
JP5147866B2 (ja) | 2007-03-15 | 2013-02-20 | メルク・シャープ・アンド・ドーム・コーポレーション | グルカン合成酵素阻害剤として有用であるピリダジノン誘導体 |
DK2137162T3 (en) * | 2007-03-15 | 2018-11-26 | Novartis Ag | Organic compounds and their applications |
US8222251B2 (en) * | 2007-09-07 | 2012-07-17 | Amgen Inc. | Pyridopyridazine compounds, compositions and methods of use |
GB0808888D0 (en) * | 2008-05-15 | 2008-06-25 | Syngenta Participations Ag | Insecticidal compounds |
US8530474B2 (en) | 2008-07-03 | 2013-09-10 | Janssen Pharmaceutica Nv | Substituted 6-(1-piperazinyl)-pyridazines as 5-HT6 receptor antagonists |
US20100029655A1 (en) * | 2008-07-11 | 2010-02-04 | Martin Robert Leivers | Processes For The Preparation Of Anti-Viral Compounds And Compositions Containing Them |
US20100041663A1 (en) * | 2008-07-18 | 2010-02-18 | Novartis Ag | Organic Compounds as Smo Inhibitors |
CA2730959A1 (fr) | 2008-07-18 | 2010-01-21 | Sanofi-Aventis | Nouveaux derives triazolo[4,3-a]pyridine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met |
JP2011528341A (ja) | 2008-07-18 | 2011-11-17 | 武田薬品工業株式会社 | ベンズアゼピン誘導体及びそれらのヒスタミンh3拮抗薬としての使用 |
FR2933982A1 (fr) | 2008-07-18 | 2010-01-22 | Sanofi Aventis | Nouveaux derives imidazo°1,2-a!pyrimidine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met |
US8216547B2 (en) | 2008-07-18 | 2012-07-10 | Janssen Pharmaceutica Nv | Radiolabelled TRP M8 receptor ligands |
JP2011528338A (ja) | 2008-07-18 | 2011-11-17 | サノフイ−アベンテイス | 新規イミダゾ[1,2−a]ピリジン誘導体、この調製方法、この医薬としての使用、医薬組成物、および新規用途、特にMET阻害剤としての用途 |
WO2010017240A2 (en) * | 2008-08-04 | 2010-02-11 | Amgen Inc. | Aurora kinase modulators and methods of use |
EP2346499A1 (en) | 2008-10-01 | 2011-07-27 | Novartis AG | Smoothened antagonism for the treatment of hedgehog pathway-related disorders |
PT2364185E (pt) * | 2008-11-03 | 2013-07-24 | Lilly Co Eli | Ftalazina dissubstituída antagonista da via hedgehog |
US7968128B2 (en) * | 2008-11-03 | 2011-06-28 | Viva Pharmaceutical Inc. | Plant extract compositions for affecting sleep |
WO2010056620A1 (en) * | 2008-11-17 | 2010-05-20 | Eli Lilly And Company | Tetrasubstituted pyridazines hedgehog pathway antagonists |
FR2939134A1 (fr) * | 2008-12-01 | 2010-06-04 | Sanofi Aventis | Derives de 6-cycloamino-3-(1h-pyrrolo°2,3-b!pyridin-4-yl) imidazo°1,2-b!-pyridazine, leur preparation et leur application en therapeutique |
-
2009
- 2009-07-15 US US12/503,565 patent/US20100041663A1/en not_active Abandoned
- 2009-07-16 EP EP09780696.2A patent/EP2318389B1/en active Active
- 2009-07-16 MX MX2011000721A patent/MX2011000721A/es active IP Right Grant
- 2009-07-16 JP JP2011517925A patent/JP5492202B2/ja not_active Expired - Fee Related
- 2009-07-16 GE GEAP200912064A patent/GEP20125624B/en unknown
- 2009-07-16 CA CA2731130A patent/CA2731130C/en not_active Expired - Fee Related
- 2009-07-16 DK DK09780696.2T patent/DK2318389T3/da active
- 2009-07-16 ME MEP-2011-6A patent/ME01290B/me unknown
- 2009-07-16 UY UY0001031991A patent/UY31991A/es not_active Application Discontinuation
- 2009-07-16 MY MYPI2011000152A patent/MY149716A/en unknown
- 2009-07-16 ES ES09780696T patent/ES2428100T3/es active Active
- 2009-07-16 BR BRPI0916375A patent/BRPI0916375A2/pt not_active IP Right Cessation
- 2009-07-16 AU AU2009272719A patent/AU2009272719B2/en not_active Ceased
- 2009-07-16 UA UAA201100571A patent/UA105181C2/uk unknown
- 2009-07-16 SI SI200930700T patent/SI2318389T1/sl unknown
- 2009-07-16 KR KR1020117003664A patent/KR101312122B1/ko active IP Right Grant
- 2009-07-16 PE PE2011000050A patent/PE20110153A1/es not_active Application Discontinuation
- 2009-07-16 AR ARP090102720A patent/AR072816A1/es unknown
- 2009-07-16 PL PL09780696T patent/PL2318389T3/pl unknown
- 2009-07-16 RS RS20130375A patent/RS52934B/en unknown
- 2009-07-16 WO PCT/EP2009/059138 patent/WO2010007120A1/en active Application Filing
- 2009-07-16 EA EA201100192A patent/EA020710B1/ru not_active IP Right Cessation
- 2009-07-16 PT PT97806962T patent/PT2318389E/pt unknown
- 2009-07-16 CN CN2009801347026A patent/CN102143958B/zh not_active Expired - Fee Related
- 2009-07-16 NZ NZ590483A patent/NZ590483A/en not_active IP Right Cessation
- 2009-07-16 JO JO2009269A patent/JO2843B1/en active
- 2009-07-17 TW TW098124316A patent/TWI431001B/zh not_active IP Right Cessation
-
2011
- 2011-01-06 IL IL210494A patent/IL210494A/en not_active IP Right Cessation
- 2011-01-07 ZA ZA2011/00205A patent/ZA201100205B/en unknown
- 2011-01-10 CR CR20110014A patent/CR20110014A/es unknown
- 2011-01-14 MA MA33529A patent/MA32485B1/fr unknown
- 2011-01-17 CL CL2011000101A patent/CL2011000101A1/es unknown
- 2011-01-17 NI NI201100022A patent/NI201100022A/es unknown
- 2011-01-17 CU CU2011000011A patent/CU24027B1/es active IP Right Grant
- 2011-01-17 DO DO2011000020A patent/DOP2011000020A/es unknown
- 2011-01-18 SV SV2011003812A patent/SV2011003812A/es active IP Right Grant
- 2011-01-18 HN HN2011000193A patent/HN2011000193A/es unknown
- 2011-01-18 GT GT201100017A patent/GT201100017A/es unknown
- 2011-01-18 EC EC2011010764A patent/ECSP11010764A/es unknown
- 2011-01-19 CO CO11005445A patent/CO6351727A2/es active IP Right Grant
- 2011-09-21 HK HK11109939.2A patent/HK1155736A1/xx not_active IP Right Cessation
-
2012
- 2012-07-20 US US13/553,870 patent/US8481542B2/en active Active
-
2013
- 2013-05-30 US US13/905,686 patent/US9409871B2/en active Active
- 2013-09-10 HR HRP20130843AT patent/HRP20130843T1/hr unknown
- 2013-09-18 CY CY20131100808T patent/CY1114478T1/el unknown
- 2013-10-07 SM SMT201300114 patent/SMT201300114T1/xx unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20220154322A1 (en) * | 2019-03-07 | 2022-05-19 | Suzhou Microport Orthorecon Co., Ltd. | Preparation method and application of oxidized ceramic layer on surface of zirconium and zirconium alloy |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MY149716A (en) | Pyridazine derivatives as smo inhibitors | |
UA100684C2 (uk) | Похідні бензилу та піридинілу як модулятори сигнального шляху hedgehog | |
IN2012DN02081A (uk) | ||
PH12015502575B1 (en) | Piperidin-4-yl azetidine derivatives as jak1 inhibitors | |
UY32251A (es) | Compuestos quimicos | |
MY165728A (en) | Selective glycosidase inhibitors and uses thereof | |
SG179418A1 (en) | Inhibitors of the hedgehog pathway | |
MY165579A (en) | Synthetic methods for spiro-oxindole compounds | |
PH12013502369A1 (en) | Diazacarbazoles and methods of use | |
MX2010013682A (es) | Derivados de 2,4-diamino-l,3,5-triazina triciclicos utiles para el tratamiento del cancer y trastornos mieloproliferativos. | |
MX2014000964A (es) | Derivados aza heterociclicos sustituidos. | |
MX349550B (es) | 1,7-diazacarbazoles y metodos de uso. | |
MX2014003584A (es) | Derivados de metanosulfonamida sustituidos como ligandos de receptores vaniloides. | |
MX2014003455A (es) | Derivados de metanosulfonamida sustituidos con arilo o n-heteroarilo como ligandos de receptor vanilloide. | |
TN2011000009A1 (en) | Pyridazne derivatives as smo inhibitors | |
MX2008012824A (es) | Derivados de sulfonil-3-heterociclilindazol como ligandos de 5-hidroxitriptamina-6. | |
MA33958B1 (fr) | Derives de pyrazine et leur utilisation dans le traitement de troubles neurologiques |